Fractyl Health, Inc. (NASDAQ:GUTS) Given Average Recommendation of “Moderate Buy” by Analysts

Shares of Fractyl Health, Inc. (NASDAQ:GUTS) have earned a consensus recommendation of “Moderate Buy” from the six research firms that are currently covering the firm, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, one has given a hold rating and four have given a buy rating to the company. The average 12 month target price among analysts that have updated their coverage on the stock in the last year is $5.12.

Several equities research analysts recently issued reports on the stock. HC Wainwright reissued a “buy” rating and issued a $8.00 target price on shares of Fractyl Health in a report on Thursday, June 4th. Weiss Ratings raised shares of Fractyl Health from a “sell (e+)” rating to a “sell (d-)” rating in a report on Monday, July 6th. Canaccord Genuity Group reissued a “buy” rating and issued a $8.00 price objective on shares of Fractyl Health in a research note on Thursday, March 26th. Wall Street Zen upgraded shares of Fractyl Health from a “strong sell” rating to a “hold” rating in a research report on Saturday, May 16th. Finally, Craig Hallum assumed coverage on shares of Fractyl Health in a research note on Wednesday, July 1st. They set a “buy” rating and a $4.00 target price on the stock.

Insider Activity

In other Fractyl Health news, Director Ian Sheffield bought 35,000 shares of the business’s stock in a transaction that occurred on Wednesday, June 10th. The stock was purchased at an average price of $0.73 per share, for a total transaction of $25,550.00. Following the completion of the transaction, the director owned 35,000 shares of the company’s stock, valued at $25,550. This trade represents a ? increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director William Bradley bought 68,493 shares of the firm’s stock in a transaction that occurred on Wednesday, June 10th. The shares were acquired at an average cost of $0.73 per share, for a total transaction of $49,999.89. Following the purchase, the director directly owned 84,622 shares in the company, valued at $61,774.06. This trade represents a 424.66% increase in their position. The SEC filing for this purchase provides additional information. Insiders bought 171,493 shares of company stock worth $127,150 over the last 90 days. Company insiders own 8.52% of the company’s stock.

Institutional Investors Weigh In On Fractyl Health

A number of institutional investors have recently added to or reduced their stakes in the stock. Rosalind Advisors Inc. purchased a new stake in Fractyl Health in the 3rd quarter worth $7,950,000. Atom Investors LP purchased a new stake in shares of Fractyl Health in the fourth quarter worth about $4,143,000. 683 Capital Management LLC lifted its position in shares of Fractyl Health by 30.1% in the fourth quarter. 683 Capital Management LLC now owns 6,047,620 shares of the company’s stock worth $13,305,000 after buying an additional 1,397,620 shares in the last quarter. Pale Fire Capital SE boosted its stake in Fractyl Health by 84.5% during the first quarter. Pale Fire Capital SE now owns 5,921,045 shares of the company’s stock valued at $2,711,000 after buying an additional 2,711,103 shares during the last quarter. Finally, Accredited Investors Inc. bought a new position in Fractyl Health during the first quarter valued at approximately $46,000.

Fractyl Health Stock Performance

NASDAQ:GUTS traded up $0.00 during mid-day trading on Friday, hitting $0.79. 642,144 shares of the company traded hands, compared to its average volume of 1,355,862. The stock’s fifty day moving average price is $0.80 and its 200-day moving average price is $0.91. Fractyl Health has a one year low of $0.38 and a one year high of $2.44. The company has a quick ratio of 4.28, a current ratio of 4.28 and a debt-to-equity ratio of 1.41. The firm has a market cap of $125.76 million, a price-to-earnings ratio of -0.61 and a beta of 2.29.

Fractyl Health (NASDAQ:GUTS) last posted its quarterly earnings data on Tuesday, May 12th. The company reported $0.06 EPS for the quarter, topping the consensus estimate of ($0.17) by $0.23. Research analysts anticipate that Fractyl Health will post -0.6 earnings per share for the current fiscal year.

Fractyl Health Company Profile

Fractyl Health, Inc is a clinical-stage medical technology company focused on the development and commercialization of minimally invasive, endoscopic therapies for metabolic diseases. Headquartered in Lexington, Massachusetts, Fractyl is advancing treatments that target the underlying physiology of conditions such as type 2 diabetes, obesity and nonalcoholic fatty liver disease (NAFLD) by modifying the duodenal mucosa to improve metabolic control.

The company’s lead product, Revita® Duodenal Mucosal Resurfacing (Revita DMR), employs a catheter-based hydrothermal ablation technique to remodel the lining of the upper small intestine.